Sir, We report the first detection of a strain of Neisseria gonorrhoeae susceptible to nalidixic acid but resistant to ciprofloxacin. Although ciprofloxacin-resistant N. gonorrhoeae strains are already frequent in the UK, 1 the observation is significant because disc tests with nalidixic acid are widely used to predict fluoroquinolone susceptibility for N. gonorrhoeae, being recommended, for example, by the British Society for Antimicrobial Chemotherapy (BSAC) guidelines. 2 This practice is based on the fact that ciprofloxacin resistance is sometimes difficult to detect directly whereas isolates with even low-level resistance typically give no zone of inhibition to 30 mg nalidixic acid discs. 2 Since May 2004, Bedford Microbiology laboratory has tested N. gonorrhoeae isolates with both nalidixic acid (30 mg) and ciprofloxacin (1 mg) discs, following technical methods given in the BSAC guidelines. 2 In December 2004, we isolated N. gonorrhoeae that exhibited susceptibility to nalidixic acid but resistance to ciprofloxacin from two patients, a male and a female, both from this catchment area. Identification was confirmed by standard tests and the isolates were referred to the Sexually Transmitted Bacteria Reference Laboratory, Health Protection Agency Centre for Infections, London.
The reference laboratory confirmed the identification and found MICs of nalidixic acid and ciprofloxacin of 1.5-2 mg/L and >32 mg/L, respectively, confirming the disc diffusion results. In contrast, ciprofloxacin-resistant N. gonorrhoeae strains usually require nalidixic acid MICs ‡ 128 mg/L. 3, 4 Ceftriaxone and cefixime MICs were £0.12 mg/L and £0.25 mg/L, respectively, and neither isolate had b-lactamase. Both were typed by NG-MAST 5 and were assigned to type ST1218, thus belonging to a unique strain within the UK database. Epidemiological investigation revealed that this strain was probably acquired in India by the male patient who infected his female partner on return. Both patients were treated with oral cefixime, with clearance confirmed 2 weeks after treatment.
Bedford Microbiology Laboratory tested over 80 gonococcal isolates for fluoroquinolone susceptibility with both nalidixic acid and ciprofloxacin discs between May 2004 and March 2005 and detected only these two isolates with this unique resistance pattern. The prevalence of this type of resistance strain in the UK is unknown and will remain so unless both antibiotic discs are used to ascertain fluoroquinolone susceptibility in N. gonorrhoeae. The reference laboratory is carrying out more work to identify the mechanism of resistance and the extent of its dissemination. Until these investigations are complete, we advise laboratories to test gonococci with ciprofloxacin as well as nalidixic acid discs and to avoid fluoroquinolone therapy for infections due to isolates resistant to either agent. In Brazil, the Adolfo Lutz Institute (IAL), the public health laboratory for São Paulo state, is the National Reference Centre for pneumococcal infections. The IAL systematically receives invasive pneumococcal isolates from hospitals and regional public health laboratories, dispersed throughout the country, through the network of the national surveillance system coordinated by the Minister of Health of Brazil. Pneumococcal strains isolated from normally sterile fluids of hospitalized patients with community-acquired infections are sent voluntarily to IAL with demographic data for monitoring antimicrobial resistance. We briefly report here the increase in penicillin resistance of invasive pneumococci in Brazil between 1998 and 2003.
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At the IAL, the S. pneumoniae isolates were investigated for their penicillin resistance by MIC determination using broth microdilution methodology and interpretative criteria standardized by the Clinical and Laboratory Standards Institute/NCCLS. 3 An external Quality Assurance Program coordinated by the National Centre for Streptococcus, Edmonton, Alberta, Canada has validated the performance of testing and the results. All information was recorded using EpiInfo software version 6.04 (Centers for Disease Control and Prevention, Atlanta, GA, USA) and statistical analyses were performed using SSPS software, version 10.0 (SPSS Inc., Chicago, IL, USA). Logistic regression was applied to assess the odds ratio (OR) and respective 95% confidence intervals of the nonsusceptible pneumococci (NSP) isolation by year.
Between 1998 and 2003, 3914 pneumococci recovered from meningitis (69.4%), pneumonia (20.6%) or other invasive infections (10%) were studied. Approximately 50% were from children up to 5 years old. No significant differences were found in the frequency of isolates by clinical diagnosis and patient age, or in the criteria for sending isolates to IAL during the period of study.
Over the 6 years of the survey, the frequency of NSP Prior to 2000, resistance rates to penicillin in Brazil were lower than those found in other Latin American countries and were gradually increasing at a lower rate through the years. [4] [5] [6] However, the present data show the rapid dissemination of penicillin NSP among invasive pneumococci in Brazil after 1999, mainly associated with a high level of resistance. Thus, we record the year 2000 as a transitional period towards a progressive emergence of penicillin NSP, reinforcing the continued national surveillance to promote appropriate antimicrobial use against invasive pneumococcal infection in the region. 
